GENFIT Releases Half-Year Liquidity Contract Report

An update from Genfit SA ( (GNFT) ) is now available.

GENFIT announced the half-year report of its liquidity contract with Crédit Industriel et Commercial, revealing significant trading activity in the second half of 2024. The report indicates a balanced trading volume on both the buy and sell sides, suggesting effective management of liquidity and stable financial operations, which may reassure stakeholders about the company’s market stability and operational efficiency.

More about Genfit SA

GENFIT is a late-stage biopharmaceutical company focused on developing treatments for rare, life-threatening liver diseases, including Acute-on-Chronic Liver Failure and other serious conditions. With a rich history in liver disease research and a diversified R&D portfolio, GENFIT is known for its expertise in developing high-potential molecules and diagnostics. The company is headquartered in Lille, France, and has a significant presence in Paris, Zurich, and Cambridge, MA, USA. GENFIT is publicly traded on Nasdaq and Euronext markets.

YTD Price Performance: -6.01%

Average Trading Volume: 8,762

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $175.5M

For an in-depth examination of GNFT stock, go to TipRanks’ Stock Analysis page.